Abstract
AIM: Mitochondrial DNA dysfunction has been implicated in the pathogenesis of cardiovascular diseases. We aimed to investigate the associations of leukocyte mitochondrial DNA (mtDNA) abundance, as a proxy of mitochondrial copy numbers and function, and coronary artery disease (CAD) and heart failure (HF) in a cohort study and approximate the causal nature of these relationships using Mendelian randomization (MR) in genetic studies.
METHODS AND RESULTS: Multivariable-adjusted Cox regression analyses were conducted in 273,619 unrelated participants of European ancestry from UK Biobank (UKB). For genetic studies, we first performed MR analyses with individual-level data from the UKB using a weighted genetic risk score (GRS); two-sample MR analyses were subsequently performed using summary-level data from the publicly available three consortia/biobank for CAD and two for HF. MR analyses were performed per database separately and results were subsequently meta-analyzed using fixed-effects models. During a median follow-up of 11.8 years, cox regression restricted cubic spline analyses showed associations between lower mtDNA abundance and higher risk of CAD and HF. Hazard ratios for participants in the lowest quintile of mtDNA abundance compared with those in the highest quintile were 1.08 (95% confidence interval: 1.03, 1.14) and 1.15 (1.05, 1.24) for CAD and HF. Genetically, no evidence was observed for a possible non-linear causal effect using individual-level weighted genetic risk scores calculated in the UKB on the study outcomes; the pooled odds ratios from two-sample MR of genetically predicted per one-SD decrease in mtDNA abundance were 1.09 (1.03, 1.16) for CAD and 0.99 (0.92, 1.08) for HF, respectively.
CONCLUSION: Our findings support a possible causal role of lower leukocyte mtDNA abundance in higher CAD risk, but not in HF.
Original language | English |
---|---|
Article number | cvac182 |
Pages (from-to) | 998-1007 |
Number of pages | 10 |
Journal | Cardiovascular Research |
Volume | 119 |
Issue number | 4 |
Early online date | 20 Dec 2022 |
DOIs | |
Publication status | Published - 2 May 2023 |
Bibliographical note
FundingThis work was supported by the VELUX Stiftung (grant number 1156) (to D.H. and R.N.). J.L. was supported by the China Scholarship Council (No. 201808500155). R.N. was supported by an innovation grant from the Dutch Heart Foundation (grant number 2019T103). S.H. is supported by the Karolinska Institutet Strategic Research Area in Epidemiology and the Swedish Research Council (2019-01272).
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Data Availability Statement
Data used in the multivariable-adjusted analyses will be made available upon request in adherence with transparency conventions in medical research and through reasonable requests to the corresponding author. Data used in the Mendelian randomization analyses are all publicly available provided in the article or via a corresponding consortium.Keywords
- Mitochondrial DNA
- Coronary Artery Disease
- Heart failure
- Mendelian randomisation